• Home
  • >>>>>>>>>>>>> 2026 & BEYOND MASTER PLAN >>>>>>>>>>>>>>>>
  • Virtual Data Room (VDR) for Strategic Customized Slide Decks
  • TRAINABLE DATA ASSETS IN CORPORATE LEGACY & ORGANIZATION’s STRATEGIC MEMORY (2012 – 2025)
  • 2.0 LPBI Executive Summary
  • 1.0 LPBI Executive Summary
  • Founder’s Vision
  • Portfolio of IP Assets
  • Knowledge PORTALS System (KPS)
  • 1.0 LPBI – 2012-2020 VISTA
  • LPBI Group’s History
  • 2.0 LPBI – 2021-2025 VISION
  • BioMed e-Series
  • Press Coverage
  • Investor Relations
  • Our TEAM
  • Founder’s Bio
  • Funding, Deals & Partnerships
  • 1.0 LPBI Group News
  • 1.0 LPBI CALENDAR
  • 2.0 LPBI Group News
  • Testimonials about LPBI
  • DrugDiscovery @LPBI Group
  • Medical 3D Printing
  • e-VOICES Podcasting
  • LPBI Newsletters
  • Customer Surveys
  • Health Care INVESTOR’s Corner ($)
  • 2021 Summer Internship Portal
  • 2021-2025 Medical Text Analysis (NLP)
  • Artificial Intelligence: Genomics & Cancer
  • Blockchain Transactions Network Ecosystem
  • 1.0 LPBI Brochure
  • 2.0 LPBI Brochure
  • 2.0 LPBI – Calendar of Zooms
  • Coronavirus, SARS-CoV-2 Portal
  • LPBI India
  • SOP Web STAT
  • Synthetic Biology in Drug Discovery
  • Certificate One Year
  • NFT: Redefined Format of IP Assets
  • Audio English-Spanish: BioMed e-Series
  • Five Bilingual BioMed e-Series
  • Press Releases
  • Intangibles CIM
  • BioMed Audio Podcast Library @LPBI Group
  • Medical School Education: Use of LPBI Group’s Contents
  • ChatGPT + Wolfram PlugIn
  • Medicine with GPT-4 & ChatGPT
  • AGI, generativeAI, Grok, DeepSeek & Expert Models in Healthcare
  • Multimodal Healthcare Foundation Model
  • Cell Therapy in Regenerative Medicine, 2026 and Beyond
  • Contact Us

Leaders in Pharmaceutical Business Intelligence Group, LLC, Doing Business As LPBI Group, Newton, MA

Healthcare analytics, AI solutions for biological big data, providing an AI platform for the biotech, life sciences, medical and pharmaceutical industries, as well as for related technological approaches, i.e., curation and text analysis with machine learning and other activities related to AI applications to these industries.

Feeds:
Posts
Comments

Asset EXT-C.3.3 “The Innermost Loop” Daily Newsletters of Alex Wissner-Gross: Competitive Dynamics in the AI Revolution — Strategic Relevance to LPBI Group’s Mission

Asset EXT-C.3.3 “The Innermost Loop” Daily Newsletters of Alex Wissner-Gross: Competitive Dynamics in the AI Revolution — Strategic Relevance to LPBI Group’s Mission

 

As of 8/30/2026 the content on this topic which started to be monitored and recorded in November 2025 resides primarily in a Post in the Journal, Public Accessed

A Systematic Analysis of Competitive Dynamics in the AI Revolution — Strategic Relevance to LPBI Group’s Mission – Alex Wissner-Gross Daily Newsletters “The Innermost Loop” by KOL (March 1 – June 10, 2026, to be extended to Present)

Curators: Aviva Lev-Ari, PhD, RN and Grok/xAI

https://pharmaceuticalintelligence.com/2026/06/11/a-systematic-analysis-of-competitive-dynamics-in-the-ai-revolution-strategic-relevance-to-lpbi-groups-mission-alex-wissner-gross-daily-newsletters-by-kol-march-1-june-1/

Work-in Progress

BACKGROUND

The effort started to be recorded in several Phases:

  • Phase 1: Early recording started in November 2025 with the following series of article about AI Initiatives in Big Pharma @Grok prompt & Proprietary Training Data and Inference by LPBI Group’s IP Assets Class I, CLass II, Class III, Class V and Class X. See References, below
  • Phase 2: for a slide and an appendices in a 1.0 Master Deck, March 2026, chiefly,

Slide #29: KOL Concepts in AI Breakthroughs – Alex Wissner-Gross Subtitle: Strategic Relevance to LPBI’s AI-in-Health Portfolio & COM Tool Factory, and

Appendix #26: Corporate Perspective on Competitive Landscape in Healthcare AI & Scientific Publishing Subtitle: Platforms, Tools, and Publishing Competitors (John Snow Labs, IQVIA NLP, Elsevier, etc.) and

Appendix #33: Industrial Sector Perspective on Competitive Landscape in Healthcare AI Subtitle: Competitive Landscape – AI Platforms, Bioinformatics Companies, Genomics Companies & Potential Acquirers

Appendix #40: SUPPLEMENTAL MATERIALS Markets & Competitive Intelligence Subtitle: Full Radar Screen Logs & Detailed LPBI Relevance Mapping (Complete item-by-item records for Appendix #26 • Appendix #33 • Appendix #39)

  • Phase 3: for a slide and an appendices in a 2.0 Master Deck, March 2026, chiefly,

Appendix E#33 – Industrial Sector Perspective on Competitive Landscape in Healthcare AI

Appendix E#39 – Founder’s Radar Screen – AI in Health, Life Sciences & BioPharma

Appendix E#40 – SUPPLEMENTAL MATERIALS – Markets & Competitive Intelligence

  • Phase 4: for a slide and an appendices in SpaceXAI Deck, March 2026, chiefly,

E#39: Founder’s Radar Screen – AI in Health, Life Sciences & BioPharma

  • Phase 5: Wall 8, Page 1

Step 1: Consolidation of Materials

Step 2: Verification for Mutually Exclusive content to avoid Word Count more than ONCE

Total Word Count by Source

  1. Origin: 1.0 Master Deck – Slides:
  2. Origin: 1.0 Master Deck – Appendices:
  3. Origin: 2.0 Master Deck – Appendices:
  4. Origin: SpaceXAI Deck – Appendices:
  5. Phase 5: Wall 8, Page 1
  6. Hub
  7. Post in Journal
  8. Total [1 through 6] = 

Content Retrieved by Source

Origin: 1.0 Master Deck – Slides:

 

Origin: 1.0 Master Deck – Appendices: 

 

Origin: 2.0 Master Deck – Appendices: 

 

Origin: SpaceXAI Deck – Appendices: 

 

Origin: Phase 5: Wall 8, Page 1

 

 

 

 

 

 

REFERENCES

Share this:

  • Share on X (Opens in new window) X
  • Share on LinkedIn (Opens in new window) LinkedIn
  • Share on Facebook (Opens in new window) Facebook
  • Print (Opens in new window) Print
  • Email a link to a friend (Opens in new window) Email

Like this:

Like Loading…

  • Follow Blog via Email

    Enter your email address to follow this blog and receive notifications of new posts by email.

    Join 2,041 other subscribers
  • Recent Posts

    • FDA Moves Forward With Its Guidance Framework for Rare Disease Trials: 2026 August 3, 2026
    • Artificial Intelligence TRANSFORMS Medicine, Biotech and Healthcare, How? August 3, 2026
    • In Memoriam: Nobel Laureate J. Michael Bishop for discovery of Retroviral Oncogenes July 31, 2026
    • Companies Actively Engaging Artificial Intellegence for Drug Design: 2026 July 31, 2026
    • AI-Native Drug Discovery Landscape 2026 – How LPBI Group Differentiates in the New Era of Foundation Models July 19, 2026
    • In Memoriam: In Remembrance of Cancer Researchers who passed in 2026 July 13, 2026
    • Urgent Request for Action on Proposed Rule Affecting Federal Funding Grant Review July 7, 2026
    • 2026 Tang Prize in Biopharmaceutical Science Awarded to Three Pioneers of Cellular Immunotherapy Revolutionizing Treatments for Blood Cancers and Solid Tumors July 5, 2026
    • Protected: KOL on Competitive Dynamics: LPBI Group’s Founder’s Radar Screens on AI-in-Health, Life Sciences & BioPharma June 15, 2026
    • Tumor Infiltrating Lymphocytes (TIL) as a first of kind FDA approved immunotherapy for cancer June 12, 2026
  • Archives

  • Categories

  • Meta

    • Log in
    • Entries feed
    • Comments feed
    • WordPress.org
    • 1 2012pharmaceutical
    • 1 sjwilliamspa

Powered by WordPress.com.

WPThemes.


%d